Wooters, T., Smith, A., Pivavarchyk, M., Siripurapu, K., McIntosh, J., Zhang, Z., … Dwoskin, L. (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x

Horton, D., Siripurapu, K., Norrholm, S., Culver, J., Hojahmat, M., Beckmann, J., … Dwoskin, L. (2011). meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics, 336(3), 940-51. https://doi.org/10.1124/jpet.110.175117

Beckmann, J., Siripurapu, K., , Horton, D., Denehy, E., Vartak, A., … Bardo, M. (2010). The novel pyrrolidine nor-lobelane analog UKCP-110 cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics, 335(3), 841-51. https://doi.org/10.1124/jpet.110.172742

Dwoskin, L., Wooters, T., Sumithran, S., Siripurapu, K., Joyce, B., Lockman, P., … Bardo, M. (2008). N,N’-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. The Journal of Pharmacology and Experimental Therapeutics, 326(2), 563-76. https://doi.org/10.1124/jpet.108.136630